|
|
|
|
 DNDi, Pharco Pharmaceuticals, and the Ministry of Health Malaysia announced at the International Liver Congress in Barcelona, Spain, that they signed agreements to test an affordable hepatitis C regimen with a target price of under $300.
|
|
|
 DNDi released a paper outlining its R&D strategy for hepatitis C with details of the licensing terms reached with Pharco Pharmaceuticals, together with infographics on both the disease and the new project, and testimonies from Malaysian hepatitis C activists explaining their difficulties in accessing current treatments. »
|
|
|
 Once every four years, World Leish brings together scientists for the leading leishmaniasis event. DNDi is co-organizing World Leish 6, which takes place in Toledo, Spain, 16-20 May 2017. To accompany the event, the World Leish 6 Scientific Community and PLOS Collections call for research papers for a special PLOS WorldLeish-6 Collection, and DNDi will award prizes to 20 researchers. »
|
|
|
 Two recent developments promise to make access to malaria treatment easier: The PREGACT study presents much needed evidence that ACTs are safe and effective in pregnant women; and WHO Prequalification has extended the shelf life of ASMQ. »
|
|
|
 In a unanimous vote in the US Senate, the first annual “World Lymphedema Day” was marked on 6th March. The US Senate is the first legislature to officially recognize lymphedema as a major cause of global disability and suffering. »
|
|
|
Journal of Medicinal Chemistry:
Repositioning antitubercular 6-Nitro-2,3-dihydroimidazo[2,1-b][1,3]oxazoles for neglected tropical diseases: Structure-activity studies on a preclinical candidate for visceral leishmaniasis »
BMC Paediatrics:
An analysis of volumes, prices and pricing trends of the pediatric antiretroviral market in developing countries from 2004 to 2012 »
PLOS Neglected Tropical Diseases:
Eliminating the neglected tropical diseases: Translational science and new technologies »
|
|
|
|
Photo credits: Don Paul/DNDi, Maneesh Agnihotri/DNDi
|
|
|
|
|
|
|
|
|
